MX336071B - Formulaciones intravenosas de antagonistas de neurocinina 1. - Google Patents

Formulaciones intravenosas de antagonistas de neurocinina 1.

Info

Publication number
MX336071B
MX336071B MX2012001872A MX2012001872A MX336071B MX 336071 B MX336071 B MX 336071B MX 2012001872 A MX2012001872 A MX 2012001872A MX 2012001872 A MX2012001872 A MX 2012001872A MX 336071 B MX336071 B MX 336071B
Authority
MX
Mexico
Prior art keywords
neurokinin
antagonists
intravenous formulations
pharmaceutical compositions
methods
Prior art date
Application number
MX2012001872A
Other languages
English (en)
Other versions
MX2012001872A (es
Inventor
David Monteith
Jiansheng Wan
Pranav Gupta
Soumendu Bhattacharya
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of MX2012001872A publication Critical patent/MX2012001872A/es
Publication of MX336071B publication Critical patent/MX336071B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica, caracterizada porque comprende: (a) un compuesto de la fórmula I: o una sal farmacéuticamente aceptable del mismo (b) macrogol 15-hidroxiestearato en una cantidad de aproximadamente 0.50% a aproximadamente 10.0% en peso de la composición total; (c) un triglicérido de cadena media en una cantidad de aproximadamente 0.10% a aproximadamente 2.5% en peso de la composición total; (d) un triglicérido de cadena larga en una cantidad de aproximadamente 0.10% a aproximadamente 1.5% en peso de la composición total; y (e ) por lo menos un amortiguador, en donde la proporción en peso de macrogol 15-hidroxiestearato: triglicérido de cadena media: triglicérido de cadena larga en la composición, es de aproximadamente 5-100: 1-5: 1, y en donde el pH de la composición es de aproximadamente 6.5 a aproximadamente 8.0.
MX2012001872A 2009-08-14 2010-08-12 Formulaciones intravenosas de antagonistas de neurocinina 1. MX336071B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14
PCT/US2010/045317 WO2011019911A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Publications (2)

Publication Number Publication Date
MX2012001872A MX2012001872A (es) 2012-04-11
MX336071B true MX336071B (es) 2016-01-06

Family

ID=43586486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001872A MX336071B (es) 2009-08-14 2010-08-12 Formulaciones intravenosas de antagonistas de neurocinina 1.

Country Status (15)

Country Link
US (2) US9101615B2 (es)
EP (2) EP2464230B1 (es)
JP (2) JP5860399B2 (es)
KR (1) KR101834577B1 (es)
CN (2) CN102573475B (es)
AU (1) AU2010282483B2 (es)
BR (1) BR112012003263A2 (es)
CA (1) CA2770403C (es)
ES (1) ES2609640T3 (es)
IL (1) IL217942A0 (es)
MX (1) MX336071B (es)
RU (2) RU2017145628A (es)
SG (2) SG10201407538WA (es)
TW (2) TWI498329B (es)
WO (1) WO2011019911A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751186B (zh) 2006-04-05 2016-08-24 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法
US8178550B2 (en) * 2006-04-05 2012-05-15 Opko Health, Inc. Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CA2736195C (en) 2008-09-05 2017-05-16 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
TW201605852A (zh) * 2013-09-26 2016-02-16 美國禮來大藥廠 新穎化合物及其製備ｔａｕ造影劑及ｔａｕ造影調配物之用途
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US9974742B2 (en) * 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
CA3013288A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
WO2018027029A1 (en) * 2016-08-03 2018-02-08 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
US20190307734A1 (en) * 2016-11-21 2019-10-10 Zhuhai Beihai Biotech Co., Ltd. Formulations of rolapitant
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
WO2019005830A1 (en) * 2017-06-26 2019-01-03 Fordoz Pharma Corp. NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN108703950B (zh) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 一种罗拉吡坦的乳剂注射液
CN109453115A (zh) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 一种罗拉匹坦静脉注射乳剂及其制备方法和应用
CN109394693A (zh) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 一种罗拉匹坦乳剂及其制备方法和应用
AU2020308397B2 (en) * 2019-06-28 2026-01-08 Jiangsu Hengrui Medicine Co., Ltd. Neurokinin-1 antagonist
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
MX2023007578A (es) * 2020-12-25 2023-07-06 Shanghai Shengdi Pharmaceutical Co Ltd Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.
CA3247908A1 (en) * 2022-01-12 2025-07-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A NEUROKIN-1 ANTAGONIST PROMEDICINE COMPOUND
CA3247898A1 (en) * 2022-01-12 2025-07-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. CRYSTALLINE FORM OF A NEUROKIN-1 ANTAGONIST PRODIGITANT COMPOUND
CN119528985A (zh) 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
JPH08502510A (ja) 1992-10-28 1996-03-19 メルク シヤープ エンド ドーム リミテツド タキキニン拮抗剤としてのアリールメチルオキシメチルピペリジン
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
ATE170174T1 (de) 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
PT812195E (pt) 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
AU3716997A (en) 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
AU735760B2 (en) 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
JP3571511B2 (ja) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 経皮吸収製剤
CA2356638A1 (en) * 1998-12-23 2000-07-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
CA2373994A1 (en) 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
HK1045308A1 (zh) 1999-12-17 2002-11-22 Schering Corporation 选择性神经激肽拮抗物
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
HUP0303154A3 (en) * 2001-02-12 2009-08-28 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
JP4459621B2 (ja) 2001-11-13 2010-04-28 シェーリング コーポレイション Ｎｋ１アンタゴニスト
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
ATE358482T1 (de) * 2002-07-03 2007-04-15 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
JP2006514994A (ja) * 2003-03-13 2006-05-18 コンフォーマ・セラピューティクス・コーポレイション 長鎖および中鎖トリグリセリドを有する医薬製剤
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
HRP20080052T3 (hr) 2003-10-03 2008-02-29 Pfizer Inc. Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala
MXPA06007210A (es) 2003-12-22 2006-08-18 Schering Corp Composiciones farmaceuticas.
CN101006074B (zh) * 2004-07-01 2012-02-15 欧科生医股份有限公司 作为nk1拮抗剂的哌啶衍生物
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
AU2005311782A1 (en) * 2004-11-30 2006-06-08 Myriad Genetics, Inc. Therapeutic formulations
CN100367951C (zh) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
WO2007103869A2 (en) * 2006-03-06 2007-09-13 Wyeth Liquid and semi-solid pharmaceutical formulations and processes
US8178550B2 (en) * 2006-04-05 2012-05-15 Opko Health, Inc. Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
CN103751186B (zh) * 2006-04-05 2016-08-24 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法
CN101110758A (zh) 2006-07-21 2008-01-23 华为技术有限公司 建立紧急会话的方法、系统及代理呼叫会话控制功能
US7879867B2 (en) * 2006-08-07 2011-02-01 Palau Pharma, S.A. Crystalline antifungal compounds
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CA2736195C (en) 2008-09-05 2017-05-16 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Also Published As

Publication number Publication date
JP2016041734A (ja) 2016-03-31
SG178403A1 (en) 2012-03-29
TW201111382A (en) 2011-04-01
KR101834577B1 (ko) 2018-03-05
AU2010282483A1 (en) 2012-03-01
EP3143996A1 (en) 2017-03-22
EP2464230B1 (en) 2016-10-05
US20110038925A1 (en) 2011-02-17
JP5860399B2 (ja) 2016-02-16
WO2011019911A1 (en) 2011-02-17
EP2464230A4 (en) 2013-01-02
RU2017145628A (ru) 2019-02-19
AU2010282483B2 (en) 2014-09-04
CA2770403A1 (en) 2011-02-17
ES2609640T3 (es) 2017-04-21
CN105503870A (zh) 2016-04-20
TWI498329B (zh) 2015-09-01
JP2013501806A (ja) 2013-01-17
KR20120060215A (ko) 2012-06-11
US20160024092A1 (en) 2016-01-28
RU2642234C2 (ru) 2018-01-24
MX2012001872A (es) 2012-04-11
IL217942A0 (en) 2012-03-29
RU2012109405A (ru) 2013-09-20
CA2770403C (en) 2020-09-01
JP6308991B2 (ja) 2018-04-11
US9101615B2 (en) 2015-08-11
EP2464230A1 (en) 2012-06-20
BR112012003263A2 (pt) 2015-09-22
TW201604195A (zh) 2016-02-01
CN102573475B (zh) 2016-01-20
SG10201407538WA (en) 2015-01-29
CN102573475A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
MX336071B (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
IN2014MN02598A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2012DN03337A (es)
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
IN2012DN04868A (es)
TN2012000105A1 (en) Spirolactam derivatives and uses of same
IN2012DN01232A (es)
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
TN2014000060A1 (en) Benzothiazolone compound
IN2012DN01234A (es)
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
WO2012008765A3 (ko) 암 치료 또는 예방용 약학 조성물